Moneycontrol Be a Pro
Get App
SENSEX NIFTY
you are here:

Advanced Enzyme Technologies Ltd.

BSE Live

Dec 11, 16:00
153.40 -2.35 (-1.51%)
Volume
AVERAGE VOLUME
5-Day
32,747
10-Day
21,654
30-Day
29,687
21,378
  • Prev. Close

    155.75

  • Open Price

    156.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Dec 11, 15:59
153.45 -2.25 (-1.45%)
Volume
AVERAGE VOLUME
5-Day
53,948
10-Day
72,558
30-Day
140,590
76,472
  • Prev. Close

    155.70

  • Open Price

    155.70

  • Bid Price (Qty.)

    153.45 (21)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Advanced Enzyme

  • Nov 28, 2019 15:32 Source: NSE

    Advanced Enzyme Technologies Limited

    Advanced Enzyme Technologies Limited has informed the Exchange regarding Disclosure of Related Party Transaction disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

  • Nov 28, 2019 15:02 Source: BSE

    Advanced Enzyme Technologies - Half-Yearly Disclosure On Related Party Transactions As Per Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015

    Pursuant to the Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 enclosed herewith is the half-yearly disclosure on Related Party Transactions, on consolidated basis prepared in accordance with the applicable accounting standards, for the half year ended September 30, 2019.

  • Nov 18, 2019 14:38 Source: NSE

    Advanced Enzyme Technologies Limited

    ADVENZYMES: The Exchange has sought clarification from Advanced Enzyme Technologies Limited with respect to announcement dated 02-Nov-2019, regarding Board meeting held on November 02, 2019. On basis of above you are required to clarify following - 1. Date of such binding agreement, if any, entered for sale of such unit/division, if any; 2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year; 3. Date of closure or estimated time of closure. The response of the Company is awaited.

  • Nov 08, 2019 16:20 Source: BSE

    Advanced Enzyme Technologies - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Earning Call Transcript Advanced Enzyme Technologies Limited Q2 FY 2020

  • Nov 04, 2019 19:09 Source: BSE

    Advanced Enzyme Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Concall with Fidelity International, Singapore on 5th November 2019.

  • Nov 04, 2019 18:55 Source: BSE

    Advanced Enzyme Technologies - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed copy of the newspaper publication of 'Extract of Un-audited Consolidated Financial Results for the quarter & half year ended September 30, 2019' published in The Free Press Journal and Navshakti on November 3, 2019.

  • Nov 02, 2019 13:22 Source: BSE

    Advanced Enzyme Technologies - Announcement under Regulation 30 (LODR)-Change in Directorate

    The Board in its meeting held on 2nd November 2019 has approved the appointment of Dr. Sunny Sharma (DIN: 02267273), as an Additional Director (Non-Executive) on the Board of the Company with immediate effect, to hold office upto the ensuing Annual General Meeting of the Company. A brief profile of Dr. Sunny Sharma is enclosed herewith as Annexure-II

  • Nov 02, 2019 13:18 Source: BSE

    Advanced Enzyme Technologies - Announcement under Regulation 30 (LODR)-Investor Presentation

    Revised Earnings Presentation, with slight change in slide no. 7 (in PAT Q2FY20)

  • Nov 02, 2019 13:12 Source: BSE

    Advanced Enzyme Technologies - Outcome Of Board Meeting Held On November 02, 2019

    Approval of the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and half year ended September 30, 2019. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2019 along with the Limited Review report issued by B S R & Co. LLP, Statutory Auditors of the Company as Annexure - I. Earnings Presentation for the quarter and half year ended September 30, 2019.

  • Nov 02, 2019 12:47 Source: BSE

    Advanced Enzyme Technologies - Outcome of Board Meeting

    Board of Directors in its meeting held on November 02, 2019 (commenced at 11:20 a.m. and concluded at 12:15 p.m.) has inter-alia, transacted the following business: ? Approval of the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter and half year ended September 30, 2019. ? appointment of Dr. Sunny Sharma (DIN: 02267273), as an Additional Director (Non-Executive) on the Board of the Company with immediate effect, to hold office upto the ensuing Annual General Meeting of the Company. ? Approved the discontinuation of operations & closure of wholly owned subsidiary of the Company in Malaysia, Advanced Enzymes (Malaysia) Sdn. Bhd. (''AEM'') and to initiate the process of closure thereto, since the company is not giving the desired results.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Nov 02, 2019
Remark : Quarterly Results